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ABSTRACT
Purpose The purpose of this work is to demonstrate rapid
intradermaldelivery ofup to1.5mLofformulationusinga hollow
microneedle delivery device designed for self-application.
Methods 3M’s hollow Microstructured Transdermal System
(hMTS) was applied to domestic swine to demonstrate delivery
of a variety of formulations including small molecule salts and
proteins. Blood samples were collected after delivery and
analyzed via HPLC or ELISA to provide a PK profile for the
delivered drug. Site evaluations were conducted post delivery to
determine skin tolerability.
Results Up to 1.5 mL of formulation was infused into swine at
a max rate of approximately 0.25 mL/min. A red blotch, the
size of the hMTS array, was observed immediately after patch
removal, but had faded so as to be almost indistinguishable
10 min post-patch removal. One-mL deliveries of commercial
formulations of naloxone hydrochloride and human growth
hormone and a formulation of equine anti-tetanus toxin were
completed in swine. With few notable differences, the resulting
PK profiles were similar to those achieved following subcutane-
ous injection of these formulations.
Conclusions 3M’s hMTS can provide rapid, intradermal
delivery of 300–1,500 µL of liquid formulations of small
molecules salts and proteins, compounds not typically com-
patible with passive transdermal delivery.
KEY WORDS transdermaldrugdelivery.microneedles.
intradermal.hollowmicrostructures.MTS
INTRODUCTION
Transdermal patches have long been used for the admin-
istration of small-molecule lipophilic drugs that can be
readily absorbed through the skin. This non-invasive
delivery route is advantageous for the administration of
many drugs incompatible with oral delivery, as it allows for
direct absorption of the drug into the systemic circulation,
by-passing both the digestive and hepatic portal systems
which can dramatically reduce the bioavailability of many
drugs. Transdermal delivery also overcomes many of the
challenges associated with subcutaneous injection by greatly
reducing patient discomfort, needle anxiety, risk of acci-
dental needle stick injury to the administrator and issues
surrounding sharps disposal (1,2).
Despite these many advantages, transdermal delivery of
drugs is confined to classes of molecules compatible with
absorption through the skin. Delivery of small molecule
salts and therapeutic proteins are not typically viable with
traditional transdermal delivery, as the skin provides an
effective protective barrier to these molecules even in the
presence of absorption-enhancing excipients (2).
The use of microstructure– or microneedle-assisted
transdermal delivery has long been proposed as a means
of capitalizing on the benefits of, while simultaneously
mitigating the challenges associated with, traditional trans-
dermal delivery. Small needles or projections, usually less
than 2 mm in length, can be inserted into the skin with
minimum patient discomfort and, given the small hole
created, with minimal risk of post-injection infection,
bleeding, or risk of inadvertent IV injection for an
intradermal administration. In addition, microneedles
reduce risk to the injection administrator, as accidental
puncture of the skin is nearly impossible with these small
projections (3).
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needles has been demonstrated and described in the
technical literature (4–9). In 2007, Haq et al. conducted a
study on healthy volunteers comparing the injection pain
and resulting tissue damage between two different types of
microneedles, and a 25-gauge hypodermic needle. Study
subjects reported significantly less pain upon injection with
the microneedles, and researchers noted that skin trauma
was less and injection site healing was faster with micro-
needles (4). In a 2002 study, researchers at Becton
Dickinson (BD) Technologies reported the results of a
human clinical study demonstrating delivery of vaccines
using flat-headed, solid microneedles. Effective delivery of
vaccine was demonstrated with minimal discomfort or skin
irritation noted by the clinical subjects (5).
In 2003, McAllister et al. reported injection of up to
32 microliters (µL) of insulin into hairless rats with induced
diabetes using a glass microneedle device. In this study, a
single glass microneedle was drilled into the dorsal skin, and
the insulin formulation was infused at a pressure of 10 lbs
per square inch (psi) over 30 min. Analysis of blood samples
indicated a statistically significant and dose-dependent drop
in blood glucose levels over a 5-h period (6). A similar study
was conducted by Nordquist et al. using a microneedle-
based infusion patch to deliver insulin to rats to provide
glycemic control (7).
More recently, a microneedle-based syringe device has been
utilized for intradermal delivery of influenza vaccines.Successful
administrations of 100 and 200 µL doses of the vaccine were
achieved in human patients. Although local site reactions were
more frequent in the intradermal group when compared to the
IM injection group, these reactions were mild and transient (8).
In 2009, delivery of insulin to diabetic human patients was
demonstrated using a single microneedle inserted into the skin
using a custom-made rotary drilling device. The max volume
delivered in this study was approximately 300 µL administered
at a rate of 1,000 µL/min (9).
Biopharmaceuticals are pharmaceutical compounds de-
rivedfromhuman, animal or microbial sources(4). According
to the pharmaceutical research firm, IMS Health, global
sales of biologics rose over 12% in 2007, a growth rate
roughly double that of classic small-molecule-based pharma-
ceutical products; biopharmaceuticals account for 25% of the
pharmaceutical development pipeline (10). Recent estimates
indicate that the demand for biopharmaceutical products
rose to nearly $70 billion in 2008. Monoclonal antibodies,
the fastest growing class of biopharmaceutical compounds,
are generally engineered to target specific diseases such as
cancer, macular degeneration and rheumatoid arthritis (11).
The production of biopharmaceuticals is extremely
resource intensive, and as a result, biopharmaceuticals are
often significantly more costly than traditional chemical
pharmaceuticals. For this reason, high efficiency, from
production in the manufacturing facility through delivery
to the patient, is required (10). The vast majority of
biopharmaceutical products currently have dosing require-
ments in excess of 0.5 mL; these volume requirements place
added burdens on the delivery system as they outstrip the
capabilities of many delivery technologies (11). The
efficiency and volume demands, coupled with the relative
instability of these protein- and peptide-based molecules,
mean that biopharmaceuticals are nearly universally in-
compatible with oral, inhalation or traditional transdermal
delivery technologies. They typically require administration
via a syringe injection or IV infusion (12), delivery options
that can cause pain, deep tissue trauma, and anxiety—all
factors that may adversely effect patient compliance.
Although much progress has been made in the development
of microneedle-based systems for transdermal delivery,
most commercially viable devices that provide intradermal
delivery of liquid formulations remain confined to relatively
small volumes, typically < 200 µL.
The 3M hollow Microstructured Transdermal System
(hMTS) is designed to allow relatively pain-free and fast
intradermal delivery of a high volume of a liquid drug
formulation to the highly vascularized dermal layer of skin.
The hMTS array is a disk comprised of evenly spaced
microneedles connected to a conventional glass cartridge.
Delivery of the liquid formulation through the micro-
structures is powered by a spring. The device applies the
microstructures into the skin to a depth sufficient to
penetrate the stratum corneum and the epidermis and
create direct access to the dermis.
The hMTS is a fully integrated microneedle delivery
device designed for self administration. The volume
capabilities of the device exceed those of traditional ID
injection and make the hMTS device a viable delivery
option for many biopharmaceutical therapeutics currently
available for delivery only with a conventional syringe or an
autoinjector. The hMTS system provides efficient, intra-
dermal delivery of pharmaceutical formulations of 0.5–
1.5 mL. The delivery time is on the order of minutes versus
seconds (as is needed for a syringe or auto injector), and the
delivery surface is spread across a 1 cm
2 array versus a single
point source provided by a syringe.
During in vivo studies in swine, the hMTS device was
used to deliver 1,500 µL of placebo formulation in as little as
2–6 min. A red, array-sized blotch and a small wheal or dome
isobservedimmediatelyafterpatchremoval,butfadessoasto
bealmostindistinguishablewithin10minpost-patchremoval;
the wheal is resolved to the touch after about 40 min post-
infusion. Deliveries of up to 1,500 µL, using delivery rates up
to 100 µL/min, were repeated using a dilute isotonic
methylenebluesolutiontoenablevisualizationofthedelivery.
Deliveryofa1µg/mLcommercialformulationofnaloxone,a
2 mg/mL formulation of hGH and a 57 mg/mL formulation
32 Burton et al.of a polycolonal antibody were also demonstrated. Blood
samples collected and analyzed after delivery indicate PK
profiles similar to those achieved following administration of
the same amount of formulation by subcutaneous injection.
MATERIALS AND METHODS
Microneedle Array and Integrated Delivery Device
The polymeric hMTS array (3M, St. Paul, MN) is 1.27 cm
2
and consists of eighteen 500–900 µm microstructures shaped
like mini-hypodermic needles. Each structure has a 10–
40 µm cannula that allows fluid communication between the
microstructures and the back of the array (Fig. 1).
The array is integrated into the device which includes an
application spring, a glass cartridge API reservoir and a
spring for delivery. The device is held to the skin with an
adhesive patch and is designed to be worn on the upper
arm or upper thigh (Fig. 2).
Animal Models and Skin Preparation
Hairless Guinea Pigs (HGP)
Male HGPs were ordered from Charles River Laboratories
(Wilmington, MA) under a 3M IACUC-approved animal
use application and used according to that protocol. All
animals used in this study weighed 0.8–1 kg. HGPs were
used to characterize the depth of penetration associated
with the microstructures.
Domestic Swine
Testing was conducted on female domestic swine approx-
imately 6–18 weeks old and weighing approximately 10–
35 kg, obtained under a 3M IACUC-approved animal use
application. During delivery and throughout the studies,
the swine were maintained under anesthesia with an
isoflurane (2–5%) oxygen mix. Deliveries were performed
on the ham of the swine which was shaved first using a
surgical clipper (clip blade #50) and then with a Schick 3
razor using a small amount of Gillette Foam shaving cream.
After shaving, the site was rinsed with water, patted dry and
then wiped with iso-propyl alcohol (Phoenix Pharmaceutical,
Inc., St. Joseph, MO).
Penetration Experiments
Microstructure Preparation and Evaluation
To prepare the microstructures for depth of penetration
(DOP) determination, the hMTS arrays were coated with
45 μl of a 0.08% w/v Rhodamine B dye (Sigma Aldrich, St.
Fig. 1 hMTS polymeric
microneedle array and a single
microstructure.
Fig. 2 hMTS integrated device
which includes A actuator, B glass
injection cartridge, C delivery
spring, D adhesive, E hollow
microstructured array, and F)
application spring.
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3 0m i n .T h ea r r a y sw e r ei n s e r t e di nt ot h eH G P sa n ds w i n e
and allowed to remain in the animals for 10 min before
removal. The structures were imaged under bright field
microscopy before and after array application using a Nikon
ME600 microscope (Nikon, Melville, NY) equipped with a
digital camera and Image Pro Plus software (Media Cyber-
netics, Inc., Bethesda, MD). Image Pro Plus allows for
measurementofthedistance fromthetipofthe microstructure
tothepointonthemicrostructurewheretheRhodamineBdye
is no longer wiped off due to insertion into the skin. All images
were captured using the 10× magnification eyepiece.
To ensure sufficient durability of the microstructures, the
array was pressed against a non-elastic surface with
increasing amounts of weight. Upon removing the array
from the skin, the arrays were inspected microscopically to
evaluate the integrity of the microstructures.
Methylene Blue Staining
Penetration of the stratum corneum by the microstructures
was assessed by staining the application site with a
methylene blue solution after removal of the array. Once
the array was removed, a hilltop chamber was attached to
the skin immediately surrounding the application site. The
chamber was filled with a mixture of 2 mg/mL methylene
blue (Aldrich, Milwaukee, WI) and 0.02 mg/ml Tween 80
in water. The dye/Tween mix was allowed to stay in
contact with the skin for 10 min. At the end of the staining
period, the chamber was removed and the skin site cleaned
with water. A photograph of the site was taken upon
removal of the hilltop chamber to document the effect of
staining.
Delivery Experiments
Dextrose
General characterization of delivery parameters was completed
using a 5% Dextrose, USP, solution for injection (Baxter
H e a l t h c a r e ,D e e r f i e l d ,I L ) ;t h es o l u t i o nw a su s e da sr e c e i v e d .
Methylene Blue
The 0.001% methylene blue solution (Aldrich, Milwaukee,
WI) was prepared using sterile water and was filtered prior
to administration.
Naloxone
A commercial formulation (1 mg/mL) of naloxone hydro-
chloride (International Medication Systems, Ltd., So. El
Monte, CA) was used for hMTS delivery and injection.
Human Growth Hormone
The hGH (Calbiochem, Trenton, NJ) was formulated at
2 mg/mL with 5% dextrose in water prior to delivery. The
hGH administered by injection was the commercial
formulation Humatrope (Lilly France, SAS, Fergersheim,
France), also a 2 mg/mL formulation.
Equine Tetanus Anti-Toxin (ETAT)
A polyclonal IgG formulation was developed as a model for
a therapeutic monoclonal antibody. Filtered horse serum
containing high levels of anti-tetanus toxin antibodies
(Colorado Serum Company, Denver, CO) was processed
using Protein-A to create an IgG-polyclonal pool. This
fraction was sterile filtered then aseptically concentrated
and buffer exchanged to a final concentration of 57 mg/mL
IgG in 4.25% dextrose and 75 mM NaCl. This antibody
concentration is in the range of commercial monoclonal
antibody formulations, such as Humira® (Abbott), currently
administered as a 50 mg/mL injectable.
Injection Experiments
The same formulations used for delivery via hMTS were
administered to the swine via subcutaneous injection using
a 23-gauge needle and 1-mL syringe. In all cases, the
subcutaneous injections were administered behind the right
shoulder of the swine.
Serum Naloxone Determination
At each time point, 1.5–2 mL of whole blood was collected
from the ear vein of the swine using a Vacutainer
Collections Set (Becton Dickenson & Co., Franklin Lakes,
NJ). The blood was allowed to set at room temperature for
at least 30 min prior to being centrifuged at 1,500 rpm for
10 min. After centrifugation, the serum was separated from
the whole blood and stored cold until extraction.
Room temperature serum samples were prepared using
solid phase extraction cartridges (Phenomenex, Torrance,
CA). Cartridges were conditioned with methanol (EMD
Chemicals, Inc., Gibbstown, NJ) and equilibrated with
reagent grade water before loading with the serum samples.
Serum was washed with 2 mL of 5% methanol in reagent
grade water and naloxone eluted with 100% methanol.
The eluent was collected in a 14 mL glass tube or a 16×
100 mm tube and dried under 15 psi of nitrogen in a 37C
water bath.
Extracts were reconstituted with 5% acetonitrile/95%
0.1% formic acid (Alfa Aesar, Ward Hill, MA) in water,
transferred to microcentrifuge tubes (Eppendorf, Westbury,
NY) and centrifuged at 14,000 rpm for 10 min.
34 Burton et al.Extracts were quantitatively analyzed using LCMSMS.
Separation was achieved using an Agilent Eclipse XDB-
C18 column (Agilent Technologies, Wilmington, DE)
in sequence with a Phenomenex C18 Guard Column
(Phenomenex, Torrence, CA); the mobile phase was 0.1%
formic acid and acetonitrile; the formic acid was ramped
from 95% to 10% over 1 min. A Sciex API3000 triple quad
mass spectrometer (Applied Biosystems, Foster City, CA)
running in positive ion mode using a Turbo IonSpray
interface was used to quantitatively monitor the product
ions resulting from the following m/z transitions:
328.17→310.10 and 342.16→324.30. The linear range
for naloxone was 0.1 to 100 ng/mL evaluated using a 1/x
curve weighting.
Various sizes of swine were dosed, so to normalize blood
naloxone levels with respect to swine weight, the blood
naloxone levels were multiplied by a conversion factor of
62 mL blood/kg of swine weight and then multiplied by the
weight of the swine at dosing (kg). Final results are plotted
as µg naloxone/swine.
Serum hGH Determination
At each time point, approximately 2 mL of whole blood
was collected from the ear vein of the swine using a
Vacutainer Collections Set and transferred into a Serum
Separator Tube (Becton Dickenson & Co., Franklin Lakes,
NJ). The blood was allowed to clot at room tempera-
ture for at least 30 min prior to being centrifuged
1,000×g for 15 min at 4C. Serum was stored ≤-20C until
analysis.
Serum samples were analyzed using an appropriate
ELISA kit (Quantikine hGH Immunoassay, R&D Systems,
Minneapolis, MN) as per instructions packaged with the kit.
Serum ETAT Determination
At each time point, 3 mL of whole blood was collected
from the ear vein of the swine using a Vacutainer
Collections Set and transferred into a Serum Separator
Tube (Becton Dickenson & Co., Franklin Lakes, NJ).
The blood was allowed to clot at room temperature for
at least 30 min prior to being centrifuged at 3,000 rpm
f o r1 0m i n .S e r u mw a sf r o z e no nd r yi c ea n ds t o r e d
≤-20°C until analysis.
Serum samples were analyzed for equine anti-tetanus
IgG using an ELISA developed in house. Briefly, 96-well
MaxiSorp
TM microtiter plates (Nunc Thermo Fisher
Scientific, Rochester, NY) were coated overnight with
tetanus toxoid for in vitro use (Statens Serum Institute,
Copenhagen, DK) at 0.23 Lf per well in 50 mM carbonate-
bicarbonate buffer pH 9.6 (Sigma, St Louis, MO) and
blocked with 0.1% ELISA-grade bovine serum albumin
(Calbiochem EMDBiosciences, San Diego, CA) diluted in
phosphate-buffered saline (PBS; HyClone Thermo Fisher
Scientific, Waltham, MA). Plates were washed with PBS,
0.05% Tween 20 (Sigma, St. Louis, MO). Serum samples
were applied and plates incubated for 2 h a 37°C. Plates
were washed and incubated with rabbit anti-equine IgG
(H + L)-horseradish peroxide conjugate (GeneTex, Irvine,
CA) at 37°C for 1 h. Plates were washed again,
and 3,3´,5,5´- Tetramethylbenzidine Substrate Solution
(Calbiochem) was applied. Color was allowed to develop
for 10–20 min, then stopped by application of 1N H2SO4.
Plates were read at 450 nm using a SpectraMax 384Plus
(MDS Molecular Devices, Sunnyvale, CA). Anti-toxin units
were read off of a standard curve of filtered commercial
Tetanus Anti-Toxin, Equine Origin (Professional Biological
Supply, Denver, CO) diluted in normal porcine serum (in-
house reagent) run on each plate. Undiluted standard was
assigned a concentration of 300 anti-toxin units/mL.
RESULTS
Penetration and DOP in HGPs and Swine
Based on the technical literature, and considering the size
of the microstructures, it was determined that a force of
0.004–0.16 N per microstructure is required for pene-
tration of the stratum corneum (13). With the hMTS
array, tip bending occurred when approximately 245 N of
force was applied to the array (18 structures). Microscopic
inspection of the arrays following in-vivo insertion was
conducted; no structures were fractured or broken off of
the array.
Figure 3 shows an application site on a HGP after patch
removal before and after staining with methylene blue; the
red color in Fig. 3a is due to staining from the Rhodamine
B dye coated on the microstructures prior to application;
no blood was observed during or after application.
The penetration of the stratum corneum by each of the
18 microstructures is evident from the pattern of blue dots
in Fig. 3b.
The DOP experiments were completed for the 500 µm
structures in both HGPs and in domestic swine and in
domestic swine for the 900 µm structures; the results from
the insertion studies are summarized in Table I.
For the 900 µm structures applied into swine, the
average inter-array variability was 12% and ranged from
7–23%.
Visual Site Assessment
Although HGPs are an appropriate model for character-
ization of DOP, these animals do not have sufficient surface
High-Volume Microneedle Delivery 35vasculature for easy blood sampling and thus are not easily
amenable to the development of a PK profile. Some studies
cited in the literature utilize a rat model (6, 7), but these
studies provide a poor correlation to human skin both with
respect to dermal thickness and physiology. The domestic
swine was chosen for the important dermal physiologic
similarities to humans. Additionally, the domestic swine
demonstrates similar intradermal pharmacokinetics to
humans (14).
Several infusions of up to 1.5 mL were conducted using
a sterile 5% dextrose or 0.001% methylene blue solution.
Once the formulation had been delivered, the device was
allowed to stay in place for up to 10 min to minimize the
potential for leaking. Figure 4 shows the results of an
800 µL intradermal infusion of a 0.001% methylene blue
formulation into swine.
The skin is dry to the touch after patch removal; the
deep blue of the infused formulation provides a visual
assessment of the treatment. Each blue spot on the skin
corresponds to one of the eighteen hollow microstructures
on the array. Although the dye appears somewhat smeared
(diffused) after 9 min, the blue stain remained, essentially
unchanged 24 h later, although the wheal disappeared in
under an hour. It is likely that the dye stains the tissue and,
in this sense, is probably not an effective indicator of
intradermal infusion patterns post delivery.
Figure 5 shows skin tolerability to a 1 mL delivery of 5%
dextrose immediately following delivery with the hMTS
device and then at 10 min and 30 min post-delivery.
Although the delivery site shows a wihish ring immediately
following delivery, note that this is not the “raised white
tense papule” that others have associated with more
conventional intradermal delivery such as the Manoux
technique (15).
Upon removal of the hMTS patch after delivery, a small
amount (1-3 µL) of formulation is typically observed on the
surface of the skin. When this fluid is removed by gentle
wiping with a tissue, no additional fluid is observed. A
pinkish blotch, the size of the hMTS array, is typically seen
upon patch removal, but the blotch fades so as to become
nearly indistinguishable within 5 min. A small dome, again
approximately the size of the hMTS array, was observed on
the swine skin as well. The dome yielded but did not “leak”
under gentle pressure. The dome was resolved, both
visually and by touch, within 40 min of removing the
application patch.
Pharmacokinetics—In-Vivo Naloxone Delivery
In an effort to better characterize the delivery, a 1 mg/mL
commercial formulation of naloxone was infused into the
swine using the hMTS POC device. Naloxone is a µ-opioid
receptor competitive antagonist used primarily to combat
overdose of drugs such as heroin. Typically administered
intravenously for fast response, naloxone is only about 2%
bioavailable when administered orally. Naloxone is well-
absorbed but is nearly 90% removed during first pass.
Literature review indicates that the half-life of naloxone in
human adults is 30–81 min and considerably longer
(approx. 3 h) in children. Naloxone is excreted in the urine
as metabolites (16). In this study, naloxone is used as a
marker drug and was not chosen for any therapeutic value.
500µm structures
in HGPs
500µm structures
in Swine (ham)
900µm structures
in Swine (ham)
Number of measurements 108 108 288
Average (µm) 210 µm 250 µm 612 µm
Standard deviation (µm) 30 µm 40 µm 99 µm
Relative standard deviation 15% 16% 16%
Table I Summary of DOP
Data Collected in Either Hairless
Guinea Pigs or Domestic
Swine (standard deviation
and relative standard deviation
refer to intra-array variability)
Fig. 3 HGP skin after hMTS
patch removal and before a (red
color is due to Rhodamine B
coated on the microstructure
prior to application) and b after
staining of the site with methylene
blue.
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comparing the PK profiles generated after hMTS infusion
and subcutaneous injection. A comparative graph of
naloxone blood levels versus time by delivery route is shown
in Fig. 6.
The areas under the curves (AUCs) associated with the
average PK profile for each group are similar. When
delivered via subcutaneous injection, naloxone has a very
rapid Tmax (10 min). In each trial, the Tmax for the profile
resulting from hMTS administration of naloxone occurred
at 30 min; the relatively slow Tmax is not surprising given
that the 1 mL hMTS administration took more than 5 min
to complete.
Figure 7 shows the hMTS delivery site 10 min post-
delivery of 1 mL of naloxone hydrochloride.
Following delivery of the naloxone hydrochloride for-
mulation, the site of application is slightly raised and may
show a white ring for the first minute or two following
delivery; this quickly fades. The site remains slightly pink
for 10–15 min after delivery is complete.
Pharmacokinetics—In-Vivo hGH Delivery
Human growth hormone (hGH) is a polypeptide hormone
with a molecular weight of approximately 22 kDa. Thera-
peutically, hGH is used to treat a number of conditions
including chronic renal failure, Turner syndrome and growth
failure in children, during which it may be administered as a
daily injection. Like most proteins, hGH is not readily
compatible with oral administration (12).
Two groups of three similarly sized swine were adminis-
tered hGH either by the hMTS device or via subcutaneous
injection. Blood samples, collected at specified time points
through an 8-h period, were analyzed for hGH. Compara-
tive PK profiles were generated and are shown in Fig. 8.
Pharmacokinetics—In-Vivo ETAT Delivery
The ETAT formulation was developed in an effort to
design a PK model for monoclonal antibody therapies. The
polyclonal ETAT fraction provides measurable activity
(binding to tetanus toxoid) and specificity (detection with
an anti-equine conjugate), thus verifying stability of the IgG
molecule, and is a reasonable model for a monoclonal
antibody administration. Most monoclonal antibodies are
administered via injection or infusions once a week, once a
month or once every other month. This class of therapeu-
tics is generally not compatible with oral administration as
they are destroyed in the digestive system (12). ETAT was
formulated at 57 mg IgG /mL, a concentration similar to
Fig. 5 Series of images 0, 10 and 30 min post-delivery of 1 mL of dextrose.
Fig. 4 Images of intradermal
infusion of a 0.05% methylene
blue formulation in swine at T=0
and T=9 min post-patch removal.
Note that skin is dry to the
touch.
High-Volume Microneedle Delivery 37certain marketed mAb products. The comparative PK
profiles (hMTS versus subcutaneous injection) are presented
in Fig. 9.
DISCUSSION
The AUCs associated with the hMTS delivery of both
naloxone and hGH are essentially equivalent to those
resulting from subcutaneous administration. Interestingly,
in both cases, the Tmax is different between the two
delivery methods. For naloxone, the delayed Tmax (relative
to injection) is likely due to the delivery time versus the time
required for this small molecule to be absorbed systemically.
The delivery time associated with the hMTS administration
of naloxone hydrochloride was between 5–10 min (depend-
ing on the trial), very similar to the Tmax associated with the
injection.
In the case of hGH, the hMTS administration profile
reached Tmax at either 30 or 60 min, while the profiles
resulting from administrations conducted by subcutaneous
injection all reached Tmax at the 150 min time point.
Although not statistically significant, the Cmax for hMTS
administration is higher than the Cmax measured from the
profiles generated following subcutaneous injection. These
differences may be attributed to the faster transport of
the macromolecule to the systemic circulation through the
highly vascularlized intradermal tissue rather than through
the more dense subcutaneous tissue. Specifically, the
lymphatic capillaries, abundant in the dermis, may be the
primary source of uptake within the intradermal space.
The lymphatic capillaries are larger than blood vessels
found adjacent and are designed for rapid uptake and
transport of large molecules. The lymphatic capillaries form
a specialized system of microvasculature to regulate
interstitial fluid pressure through a series of one-way valves
or junctions (17, 18). It seems possible that the early Tmax
and high Cmax observed in the hMTS hGH PK profile
may be attributed to primary absorption of the drug by the
lymphatic capillaries rather than by the blood vessels, which
may more commonly provide uptake in subcutaneous
injections. Utilizing this lymphatic pathway, intradermal
delivery may provide faster access to the systemic circula-
tion, especially for large molecule therapeutics.
The AUC associated with the hMTS administration is
very similar to that resulting from the subcutaneous
injection of the protein formulation. Unfortunately, the
first blood sample collected in this study was at 2 h post-
delivery. If the ETAT achieved faster absorption into the
systemic circulation via the lymphatic capillaries, as
Fig. 7 Typical hMTS Delivery Site (swine) 10 min after administration of
1 mL of Naloxone Hydrochloride.
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38 Burton et al.proposed above, the Cmax associated with the profile may
have passed before the first blood sample was collected. It
appears that ETAT administered via hMTS follows
expected elimination kinetics, even over the course of
several weeks.
CONCLUSIONS
The 3M hMTS can provide rapid transdermal delivery of
liquid formulations up to 1,500 µL, providing an option for
administration for molecules not typically compatible with
transdermal delivery. The strength and flex modulus of the
structures prevents the microneedles from fracturing or
breaking under impact forces several times higher than those
created upon application. The structures penetrate the
stratum corneum cleanly and reproducibly and provide
delivery at rates up to 300 µL/min 250–600 µm beneath the
surface of the skin. Deliveries of a small molecule salt, a
protein and a model monoclonal antibody, molecules not
compatible with traditional transdermal delivery, were
achieved with measured PK profiles and relative bioavail-
abilities similar to what are observed following subcutaneous
injection of these same formulations. Large molecules may
actually access the systemiccirculationfasterwhenintroduced
intradermally rather than via injection. The 3M hMTS
demonstrates relatively fast (5–20 min) and very efficient
transdermal delivery of large volumes of liquid formulations.
The skin shows good tolerability to the hMTS deliveries and
recovers with no long-term edema or erythema.
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Fig. 8 Comparative PK profiles
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